KROS
NASDAQKeros Therapeutics Inc.
Price$10.68-0.19 (-1.70%)
03:30 PM07:45 PM
News · 26 weeks47-20%
2026-04-192026-10-11
Mix2290d
- SEC Filings10(45%)
- Insider6(27%)
- Other5(23%)
- Dividends1(5%)
Latest news
25 items- SECKeros Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Keros Therapeutics, Inc. (0001664710) (Filer)
- PRKeros Therapeutics to Receive Additional Development Milestone Payment from Partner TakedaLEXINGTON, Mass., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced that it expects to receive a $20 million development milestone payment under the terms of the license agreement of elritercept with partner Takeda, following the dosing of the first patient in the ELRiSE MF clinical trial. ELRiSE MF is a Phase 3, multicenter, double-blind, randomized trial to compare the efficacy
- SECKeros Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Keros Therapeutics, Inc. (0001664710) (Filer)
- PRKeros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMDLEXINGTON, Mass., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced that the first patient was dosed in the Phase 2 clinical trial of rinvatercept in patients with Duchenne muscular dystrophy ("DMD"). "Dosing the first patient in our Phase 2 clinical trial of rinvatercept represents an important step in advancing our neuromuscular development strategy, and reflects the progress
- SECSEC Form EFFECT filed by Keros Therapeutics Inc.EFFECT - Keros Therapeutics, Inc. (0001664710) (Filer)
- SECSEC Form DEL AM filed by Keros Therapeutics Inc.DEL AM - Keros Therapeutics, Inc. (0001664710) (Filer)
- SECSEC Form S-3 filed by Keros Therapeutics Inc.S-3 - Keros Therapeutics, Inc. (0001664710) (Filer)
- SECKeros Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Keros Therapeutics, Inc. (0001664710) (Filer)
- PRKeros Therapeutics Announces $5 Million Share Repurchase AuthorizationLEXINGTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced that its Board of Directors has approved a $5 million share repurchase program of the Company’s common stock following receipt of a $20 million development milestone payment under the license agreement of elritercept with Takeda Pharmaceuticals U.S.A., Inc., following the dosing of the first pati
- INSIDERChief Legal Officer Cho Esther sold $46,151 worth of shares (4,485 units at $10.29), decreasing direct ownership by 11% to 35,770 units (SEC Form 4) to satisfy tax liability4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
- INSIDERDirector Newton Charles W. sold $5,675 worth of shares (551 units at $10.30) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 12,114 units (SEC Form 4)4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
- INSIDERChief Scientific Officer Lerner Lorena Raquel sold $36,715 worth of shares (3,568 units at $10.29), decreasing direct ownership by 11% to 27,559 units (SEC Form 4) (for withholding tax)4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
- INSIDERCorp. Controller & VP, Finance Tanini Annita sold $12,595 worth of shares (1,224 units at $10.29), decreasing direct ownership by 3% to 45,144 units (SEC Form 4) (withholding tax)4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
- INSIDERDirector Bienaime Jean Jacques bought $10,270 worth of shares (1,000 units at $10.27), increasing direct ownership by 5% to 19,592 units (SEC Form 4)4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
- INSIDERNew insider Tanini Annita claimed ownership of 46,368 shares (SEC Form 3)3 - Keros Therapeutics, Inc. (0001664710) (Issuer)
- SECKeros Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Keros Therapeutics, Inc. (0001664710) (Filer)
- SECSEC Form 10-Q filed by Keros Therapeutics Inc.10-Q - Keros Therapeutics, Inc. (0001664710) (Filer)
- SECKeros Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Keros Therapeutics, Inc. (0001664710) (Filer)
- PRKeros Therapeutics Reports Second Quarter 2026 Financial ResultsLEXINGTON, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today provided a business update and reported financial results for the quarter ended June 30, 2026. "We are excited to have initiated our Phase 2 clinical trial evaluating the treatment of rinvatercept in patients with Duchenne muscular dystrophy ("DMD"), marking an important milestone in the development of our
- SECKeros Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Keros Therapeutics, Inc. (0001664710) (Filer)
- PRKeros Therapeutics to Receive Development Milestone Payment from Partner TakedaLEXINGTON, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced that it will receive a $20 million development milestone payment under the terms of the license agreement of elritercept with partner Takeda, following the dosing of the first patient in the ELRiSE MDS clinical trial. ELRiSE MDS is a Phase 3, multicenter, open-label, randomized trial to compare the efficacy and sa
- SECKeros Therapeutics Inc. filed SEC Form 8-K: Leadership Update8-K - Keros Therapeutics, Inc. (0001664710) (Filer)
- INSIDERDirector Bienaime Jean Jacques bought $10,610 worth of shares (1,000 units at $10.61), increasing direct ownership by 6% to 18,592 units (SEC Form 4)4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
- INSIDERDirector Prener Anne was granted 13,786 shares (SEC Form 4)4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
- INSIDERSEC Form 3 filed by new insider Prener Anne3 - Keros Therapeutics, Inc. (0001664710) (Issuer)
KROS FAQ
7 questionsWhat does Keros Therapeutics Inc. do?
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that...Where does KROS stock trade?
Keros Therapeutics Inc. (KROS) is listed on NASDAQ.What sector and industry is KROS in?
Keros Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Keros Therapeutics Inc. go public?
Keros Therapeutics Inc. (KROS) completed its IPO in 2020.What are analysts saying about KROS?
Keros Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Wells Fargo: Overweight with a $2600.00 price target on 2025-10-20. Recent price targets range from $1500.00 to $4700.00.What companies are similar to KROS?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare KROS side-by-side with any of them on Quantisnow.How can I track KROS on Quantisnow?
Quantisnow aggregates Keros Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow KROS to receive live email and push alerts on every new disclosure.